Trials / Completed
CompletedNCT00046254
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,127 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic Acid |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2002-09-25
- Last updated
- 2012-05-02
Locations
28 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00046254. Inclusion in this directory is not an endorsement.